The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

A pivotal moment in the KRAS inhibitor market occurred in 2021 with the approval of Lumakras for the treatment of non-small cell lung cancer (NSCLC), representing a significant breakthrough for ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector ...